SERMs: Progress and future perspectives

This publication has 105 references indexed in Scilit:

• Update in Male Osteoporosis
  The Journal of Clinical Endocrinology & Metabolism, 2010
• Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial
  Circulation, 2009
• Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study
  Journal of Clinical Oncology, 2008
• Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method
  Proceedings of the National Academy of Sciences, 2008
• Toremifene Improves Lipid Profiles in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase III Study
  Journal of Clinical Oncology, 2008
• Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical Study
  Journal of Urology, 2008
• Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
  JAMA, 2006
• Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes
  JAMA, 2006
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
  The Lancet, 2002
• A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474
  British Journal of Cancer, 1971